Navigation Links
Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer

Researchers today presented preliminary safety and efficacy data for E7389 in the treatment of advanced, refractory breast cancer during the San Antonio Breast Cancer Symposium. E7389 is a synthetic analog of halichondrin B (HB), which is a natural product shown in preclinical studies to have highly potent anti-cancer activity in vitro and in vivo. Halichondrin B was originally isolated from a type of marine sponge.

This study was designed to evaluate E7389 as a monotherapy in patients with refractory breast cancer. The primary endpoint of this trial was response rate, measured using the RECIST (Response Evaluation Criteria In Solid Tumors) criteria ?a group of standards used to measure responses to treatment in solid tumors.

Of the 65 evaluable patients, 10 partial responses were confirmed at the 4th cycle assessment. Twenty-one patients had stable disease (SD). In treatment-refractory patients with advanced breast cancer this preliminary response rate (15%) appears promising.

Based on the preliminary results of this study, the predominant serious side effect related to E7389 was neutropenia (low white blood cell counts). Other side effects were considered mild to moderate and included nausea, fatigue, dehydration, arthralgias, dyspnea and neuropathy. None of the patients discontinued the study due to hematological toxicity.

"The results from this study with E7389 appear promising, and clinical research on E7389 as a treatment for breast cancer is continuing," said Sandra Silberman, MD, PhD, Associate Vice President and Global Therapeutic Area Head, Oncology at Eisai Medical Research Inc. "E7389 is an example of Eisai's human health care (hhc) commitment to satisfy unmet medical needs of patients and their families. Eisai has targeted oncology/critical care as one of three key therapeutic areas of focus," she added.

Seventy-one women were enrolled in the 28-day cycle patient group. Preliminary efficacy data for 65 patients and safety data on 48 patients are available. The 65 patients considered evaluable for response had completed at least their 2nd cycle of treatment and had a tumor assessment, which could be compared to their baseline. This study is ongoing, and final results may change from the initial analysis.

"My colleagues and I are very excited by the results of this study so far, " said Linda T. Vahdat, MD, Associate Professor of Clinical Medicine and Medical Director, Breast Cancer Program at Cornell University New York Presbyterian Hospital. "We look forward to additional studies with this novel compound."

Pre-clinical studies demonstrate that E7389 suppresses the growth of cellular microtubules, which are essential for cell division. By doing so, E7389 appears to stop the production of new cancer cells and ultimately results in the programmed death of the existing cancer cells, a process known as apoptosis.


'"/>

Source:JFK Communcations


Related biology news :

1. Wiley announces publication of Databasing the Brain
2. Nonlinear Dynamics announces more details of its global partnership with PerkinElmer
3. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
4. GlycoFi announces the first production of antibodies with human glycosylation in yeast
5. NHGRI announces new sequencing targets
6. CHAVI announces international search for genes affecting HIV response
7. NHGRI announces latest sequencing targets
8. MUHC announces a transplant first in Quebec
9. St. Jude announces breakthrough in eye cancer treatment
10. NIH announces phase III clinical trial of creatine for Parkinsons disease
11. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/3/2016)... , June 3, 2016 ... von Nepal hat ... Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung ... in der Produktion und Implementierung von Identitätsmanagementlösungen. ... Ausschreibung im Januar teilgenommen, aber Decatur wurde ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology: